CA2497867A1 - Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique - Google Patents
Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique Download PDFInfo
- Publication number
- CA2497867A1 CA2497867A1 CA002497867A CA2497867A CA2497867A1 CA 2497867 A1 CA2497867 A1 CA 2497867A1 CA 002497867 A CA002497867 A CA 002497867A CA 2497867 A CA2497867 A CA 2497867A CA 2497867 A1 CA2497867 A1 CA 2497867A1
- Authority
- CA
- Canada
- Prior art keywords
- glutamate
- drug
- inner ear
- round window
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne des méthodes et des dispositifs d'administration locale, dans l'oreille interne, d'agents modifiant la neurotransmission glutamatergique pour le traitement de troubles de l'oreille interne dus à une perte de l'audition et/ou à un acouphène induits par le glutamate.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/028519 WO2004022069A1 (fr) | 2002-09-06 | 2002-09-06 | Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2497867A1 true CA2497867A1 (fr) | 2004-03-18 |
Family
ID=31975588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002497867A Abandoned CA2497867A1 (fr) | 2002-09-06 | 2002-09-06 | Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1545551A4 (fr) |
JP (1) | JP2006502158A (fr) |
AU (2) | AU2002331830A1 (fr) |
CA (1) | CA2497867A1 (fr) |
WO (1) | WO2004022069A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
US8268866B2 (en) * | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
KR101189261B1 (ko) * | 2004-03-29 | 2012-10-09 | 앵스티띠 나셔날 드 라 쌍뜨 에 드 라 르셰르슈 메디깔 | 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도 |
US20060063802A1 (en) * | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
DE102005004343A1 (de) | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
WO2006096518A2 (fr) * | 2005-03-04 | 2006-09-14 | Neurosystec Corporation | Preparations ameliorees de gacyclidine |
JP5058163B2 (ja) * | 2005-07-22 | 2012-10-24 | メドトロニック,インコーポレイテッド | 薬剤を吐出する小型ポンプ |
EA017264B1 (ru) | 2005-09-28 | 2012-11-30 | Аурис Медикаль Аг | Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха |
CN104840416A (zh) * | 2005-09-28 | 2015-08-19 | 奥里斯医学股份有限公司 | 治疗内耳疾病的药用组合物 |
US8267905B2 (en) | 2006-05-01 | 2012-09-18 | Neurosystec Corporation | Apparatus and method for delivery of therapeutic and other types of agents |
US7803148B2 (en) * | 2006-06-09 | 2010-09-28 | Neurosystec Corporation | Flow-induced delivery from a drug mass |
US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
US8877814B2 (en) * | 2007-09-12 | 2014-11-04 | Merz Pharma Gmbh & Co. Kgaa | Titration package for neramexane and its use in the treatment of an inner ear disorder |
DE102007063210A1 (de) | 2007-12-20 | 2009-06-25 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung von Phantomphänomenen |
US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
WO2010048095A2 (fr) * | 2008-10-22 | 2010-04-29 | House Ear Institute | Traitement thérapeutique et/ou prophylactique de pathologies de l'oreille interne par la modulation du récepteur métabotropique du glutamate |
WO2010074992A2 (fr) * | 2008-12-22 | 2010-07-01 | Otonomy, Inc. | Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques |
US20110294890A1 (en) * | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
EP2790686B1 (fr) | 2011-12-12 | 2021-03-10 | Zilentin Ag | Traitement de l'acouphène par modulation du co-transporteur chlorure nkcc1 dans le système auditif |
EP3598971B1 (fr) | 2013-01-22 | 2024-03-20 | Vistagen Therapeutics, Inc. | Formes posologiques et utilisations thérapeutiques de la l-4-chlorocynurénine |
US10500392B2 (en) | 2016-08-24 | 2019-12-10 | Cochlear Limited | Monitoring stimulating assembly insertion |
WO2023038778A1 (fr) | 2021-08-19 | 2023-03-16 | Innovative Health Strategies Llc | Dispositif habitronique intelligent à auto-activation pour l'injection automatique de médicaments |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3923426A (en) | 1974-08-15 | 1975-12-02 | Alza Corp | Electroosmotic pump and fluid dispenser including same |
US4036228A (en) | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US3987790A (en) | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4016880A (en) | 1976-03-04 | 1977-04-12 | Alza Corporation | Osmotically driven active agent dispenser |
US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4111203A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4203442A (en) | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4210139A (en) | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
US4360019A (en) | 1979-02-28 | 1982-11-23 | Andros Incorporated | Implantable infusion device |
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4725852A (en) | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
US4865845A (en) | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US5057318A (en) | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5112614A (en) | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5039528A (en) * | 1989-12-11 | 1991-08-13 | Olney John W | EAA antagonists as anti-emetic drugs |
US5234693A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
SK284136B6 (sk) | 1996-02-02 | 2004-09-08 | Alza Corporation | Implantabilné zariadenie na dodávanie leuprolidu do okolitého kvapalného prostredia |
US6177434B1 (en) * | 1997-12-16 | 2001-01-23 | The United States Of America As Represented By The Secretary Of The Navy | Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms |
US8197461B1 (en) | 1998-12-04 | 2012-06-12 | Durect Corporation | Controlled release system for delivering therapeutic agents into the inner ear |
-
2002
- 2002-09-06 JP JP2004533996A patent/JP2006502158A/ja active Pending
- 2002-09-06 CA CA002497867A patent/CA2497867A1/fr not_active Abandoned
- 2002-09-06 EP EP02768820A patent/EP1545551A4/fr not_active Withdrawn
- 2002-09-06 WO PCT/US2002/028519 patent/WO2004022069A1/fr active Application Filing
- 2002-09-06 AU AU2002331830A patent/AU2002331830A1/en not_active Abandoned
-
2009
- 2009-11-03 AU AU2009233659A patent/AU2009233659A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2009233659A1 (en) | 2009-11-26 |
WO2004022069A1 (fr) | 2004-03-18 |
EP1545551A4 (fr) | 2008-10-22 |
EP1545551A1 (fr) | 2005-06-29 |
AU2002331830A1 (en) | 2004-03-29 |
JP2006502158A (ja) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009233659A1 (en) | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | |
US20100173874A1 (en) | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | |
RU2380094C2 (ru) | Способы лечения шума в ушах, индуцированного улитковой экситотоксичностью | |
US8507525B2 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
US11850244B2 (en) | Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium | |
EP1441799B1 (fr) | Dispositif d'administration de microdoses d'agents dans l'oreille | |
Vivero et al. | Dexamethasone base conserves hearing from electrode trauma‐induced hearing loss | |
WO2003071986A2 (fr) | Methode de traitement de troubles otiques | |
EP2819741B1 (fr) | Implants de médicaments solides pour l'administration intracochléaire d'agents thérapeutiques pour le traitement de troubles otiques | |
Wagner et al. | Cochlear hair cell loss in single-dose versus continuous round window administration of gentamicin | |
JP5520361B2 (ja) | グルタメート媒介神経伝達のモジュレーターの内耳への送達 | |
JP2010030985A (ja) | グルタメート媒介神経伝達のモジュレーターの内耳への送達 | |
INTRATYMPANIC | Intratympanic Pharmacotherapy | |
Qnouch | Silicone-based Implants for the treatment of the inner ear |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |